UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension

Journal of clinical pharmacology, 2016-08, Vol.56 (8), p.988-998

2016

Volltextzugriff (PDF)

Population pharmacokinetics, enzyme occupancy, and 24S‐hydroxycholesterol modeling of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, in healthy adults

Clinical and translational science, 2023-07, Vol.16 (7), p.1149-1162

2023

Volltextzugriff (PDF)

A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis

PloS one, 2013-06, Vol.8 (6), p.e66422

2013

Volltextzugriff (PDF)

Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy

Clinical cancer research, 2004-11, Vol.10 (22), p.7677-7684

2004

Volltextzugriff (PDF)

Safety, Tolerability, and Pharmacokinetics of Lasmiditan in Healthy Japanese and Caucasian Subjects

Rinshō yakuri, 2020-05, Vol.51 (3), p.119-127

2020

Volltextzugriff (PDF)

Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer

The Journal of pharmacology and experimental therapeutics, 2008-12, Vol.327 (3), p.673-682

2008

Volltextzugriff (PDF)

Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel

Pharmaceutical research, 2007-09, Vol.24 (9), p.1691-1701

2007

Volltextzugriff (PDF)

Multiscale Tumor Spatiokinetic Model for Intraperitoneal Therapy

The AAPS journal, 2014-05, Vol.16 (3), p.424-439

2014

Volltextzugriff (PDF)

Activity of drug-loaded tumor-penetrating microparticles in peritoneal pancreatic tumors

Current cancer drug targets, 2014-01, Vol.14 (1), p.70-78

2014

Volltextzugriff (PDF)

A Phase 1, Open-Label, Single-Dose Pharmacokinetic Study of Lasmiditan in Paediatric Patients with Migraine (1808)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study

Neurobiology of aging, 2019-05, Vol.77, p.37-43

2019

Volltextzugriff (PDF)

A Population Pharmacokinetic (Pk)- Pharmacodynamic (Pd) Analysis Of Peginesatide India Lysis Patients With Chronic Kidney Disease

Kidney research and clinical practice, 2012-06, Vol.31 (2), p.A60-A60

2012

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine

Clinical pharmacokinetics, 2021-06, Vol.60 (6), p.819-828

2021

Volltextzugriff (PDF)

Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol

Clinical pharmacology in drug development, 2020-07, Vol.9 (5), p.629-638

2020

Volltextzugriff (PDF)

Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates

Journal of clinical pharmacology, 2024-01, Vol.64 (1), p.94-102

2024

Volltextzugriff (PDF)

Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study

Journal of clinical pharmacology, 2020-04, Vol.60 (4), p.495-504

2020

Volltextzugriff (PDF)

An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients

Psychopharmacology, 2021-05, Vol.238 (5), p.1279-1289

2021

Volltextzugriff (PDF)

Population pharmacokinetics, enzyme occupancy, and 24 S ‐hydroxycholesterol modeling of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, in healthy adults

Clinical and translational science, 2023-07, Vol.16 (7), p.1149-1162

2023

Volltextzugriff (PDF)

Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls

Human psychopharmacology, 2020-09, Vol.35 (5), p.e2732-n/a

2020

Volltextzugriff (PDF)

A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor

Psychopharmacology, 2016-10, Vol.233 (21-22), p.3787-3795

2016

Volltextzugriff (PDF)

The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus

European journal of clinical pharmacology, 2017-03, Vol.73 (3), p.279-288

2017

Volltextzugriff (PDF)

P1‐057: A MULTIPLE ASCENDING‐DOSE STUDY OF THE PHARMACOKINETICS AND SAFETY OF LY3154207, A CENTRALLY‐ACTING DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR (D1 PAM), IN HEALTHY SUBJECTS

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_5), p.P254-P255

2019

Volltextzugriff (PDF)

A MULTIPLE ASCENDING-DOSE STUDY OF THE PHARMACOKINETICS AND SAFETY OF LY3154207, A CENTRALLY-ACTING DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR (D1 PAM), IN HEALTHY SUBJECTS

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P254-P255

2019

Volltextzugriff (PDF)

Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects

Clinical pharmacology in drug development, 2021-04, Vol.10 (4), p.393-403

2021

Volltextzugriff (PDF)

A human [11C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor

NeuroImage (Orlando, Fla.), 2016-11, Vol.141, p.10-17

2016

Volltextzugriff (PDF)

1 – 25 von 190

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(143)
Mit Volltextzugriff
(158)

Publikationsform

Sprache

Englisch
(188)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(134)
Life Sciences & Biomedicine
(90)
Humans
(62)
Male
(39)
Female
(35)
Technology
(33)
Adult
(29)
Animals
(29)
Middle Aged
(23)
Pharmacology & Pharmacy
(21)
Physical Sciences
(19)
Biological And Medical Sciences
(17)
Computer Science
(17)
Medical Sciences
(15)
Computer Science, Information Systems
(13)
Engineering
(13)
Pharmacokinetics
(13)
Aged
(12)
Studies
(12)
General & Internal Medicine
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension

Population pharmacokinetics, enzyme occupancy, and 24S‐hydroxycholesterol modeling of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, in healthy adults

A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis

Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy

Safety, Tolerability, and Pharmacokinetics of Lasmiditan in Healthy Japanese and Caucasian Subjects

Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer

Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel

Multiscale Tumor Spatiokinetic Model for Intraperitoneal Therapy

Activity of drug-loaded tumor-penetrating microparticles in peritoneal pancreatic tumors

A Phase 1, Open-Label, Single-Dose Pharmacokinetic Study of Lasmiditan in Paediatric Patients with Migraine (1808)

Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study

A Population Pharmacokinetic (Pk)- Pharmacodynamic (Pd) Analysis Of Peginesatide India Lysis Patients With Chronic Kidney Disease

Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine

Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol

Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates

Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study

An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients

Population pharmacokinetics, enzyme occupancy, and 24 S ‐hydroxycholesterol modeling of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, in healthy adults

Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls

A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor

The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus

P1‐057: A MULTIPLE ASCENDING‐DOSE STUDY OF THE PHARMACOKINETICS AND SAFETY OF LY3154207, A CENTRALLY‐ACTING DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR (D1 PAM), IN HEALTHY SUBJECTS

A MULTIPLE ASCENDING-DOSE STUDY OF THE PHARMACOKINETICS AND SAFETY OF LY3154207, A CENTRALLY-ACTING DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR (D1 PAM), IN HEALTHY SUBJECTS

Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects

A human [11C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor

Suchergebnisse filtern